These results suggest that when bladder cancer cells are exposed to Disitamab Vedotin, the upregulation of TNF, IL1B, and IL1A, followed by receptor binding, activates the NF-κB signaling pathway. This evidence concerns the gene IL1B and urinary bladder carcinoma.